Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment

被引:45
作者
Xu, Yue [1 ]
Amdanee, Nousayhah [1 ]
Zhang, Xiangrong [1 ]
机构
[1] Nanjing Med Univ, Nanjing Brain Hosp, Dept Geriatr Psychiat, 264 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
INDUCED GASTROINTESTINAL HYPOMOTILITY; CLOZAPINE-RELATED CONSTIPATION; STOOL FORM SCALE; DOUBLE-BLIND; MAINTENANCE TREATMENT; TREATED PATIENTS; COLONIC TRANSIT; OLDER PATIENTS; LONG-TERM; ROME-III;
D O I
10.1007/s40263-021-00859-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Antipsychotic-induced gastrointestinal hypomotility and, in particular, its manifestation of constipation are common adverse effects in patients with schizophrenia in clinical practice. Serious complications of antipsychotic-induced constipation include ileus, ischaemic bowel disease, colon perforation, aspiration pneumonia, and bacterial septicaemia, which can be life threatening if left untreated, especially in patients prescribed clozapine. The aim of this paper is to review the latest research on the epidemiology, clinical examination methods, pathophysiology, and treatment options and preventive measures for antipsychotic-induced constipation. While clinicians are normally aware of the overall side effects caused by antipsychotics, constipation is often an under-recognized condition despite its relatively high incidence and its impact on daily living. The incidence of constipation differs among individual antipsychotics, but more than 50% of patients prescribed antipsychotics suffer from constipation. Limited fluid intake, poor dietary habits, and a sedentary lifestyle can also worsen constipation. The mechanisms of antipsychotic-induced constipation may be antagonism of cholinergic, histaminergic, and serotonergic receptors, with both parent drug and metabolite(s) contributing to the effects on gastrointestinal motility. Numerous methods, mainly divided into scale evaluations and objective examinations, are applied to evaluate antipsychotic-induced constipation; however, objective examinations have a greater ability to identify cases of gastrointestinal hypomotility since there is often an under-reporting of symptoms in subjective reporting and scale evaluation due to a higher pain threshold, an inability to express pain sensations, and a lack of symptom awareness in these patients. Antipsychotic drug-induced constipation should be closely monitored in patients receiving these medications, with timely intervention to avoid serious gastrointestinal consequences. There is currently no consensus on the efficacy of laxatives in these patients. Further in-depth studies should explore the underlying mechanisms and devise optimal therapeutic approaches to minimize constipation during antipsychotic treatment.
引用
收藏
页码:1265 / 1274
页数:10
相关论文
共 50 条
[31]   Antipsychotic-induced tardive dyskinesia: update on epidemiology and management [J].
Widschwendter, Christian G. ;
Hofer, Alex .
CURRENT OPINION IN PSYCHIATRY, 2019, 32 (03) :179-184
[32]   Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study [J].
Wang, Man ;
Tong, Jian-hua ;
Zhu, Gang ;
Liang, Guang-ming ;
Yan, Hong-fei ;
Wang, Xiu-zhen .
SCHIZOPHRENIA RESEARCH, 2012, 138 (01) :54-57
[33]   Calcium channel blockers for antipsychotic-induced tardive dyskinesia [J].
Essali, Adib ;
Soares-Weiser, Karla ;
Bergman, Hanna ;
Adams, Clive E. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (03)
[34]   Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis [J].
Kanagasundaram, Pruntha ;
Lee, Jiwon ;
Prasad, Femin ;
Costa-Dookhan, Kenya A. ;
Hamel, Laurie ;
Gordon, Madeleine ;
Remington, Gary ;
Hahn, Margaret K. ;
Agarwal, Sri Mahavir .
FRONTIERS IN PSYCHIATRY, 2021, 12
[35]   The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis [J].
Peng, Tzu-Rong ;
Chen, Jou-An ;
Lee, Jen-Ai ;
Hsing, Chih-Pin ;
Lee, Ming-Chia ;
Chen, Shih-Ming .
SCHIZOPHRENIA BULLETIN, 2025, 51 (03) :625-636
[36]   The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review [J].
Wang, Hee Ryung ;
Woo, Young Sup ;
Bahk, Won-Myong .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (06) :301-306
[37]   Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature [J].
Fonseka, Trehani M. ;
Richter, Margaret A. ;
Mueller, Daniel J. .
CURRENT PSYCHIATRY REPORTS, 2014, 16 (11)
[38]   Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials [J].
Wu, R-R ;
Zhang, F-Y ;
Gao, K-M ;
Ou, J-J ;
Shao, P. ;
Jin, H. ;
Guo, W-B ;
Chan, P. K. ;
Zhao, J-P .
MOLECULAR PSYCHIATRY, 2016, 21 (11) :1537-1544
[39]   Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists [J].
Poyurovsky, Michael ;
Weizman, Abraham .
DRUGS, 2020, 80 (09) :871-882
[40]   Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic-Induced Weight Gain [J].
Ellinger, Lara K. ;
Ipema, Heather J. ;
Stachnik, Joan M. .
ANNALS OF PHARMACOTHERAPY, 2010, 44 (04) :668-679